Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort,European Journal of Neurology

当前位置： X-MOL 学术 › Eur. J. Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort
European Journal of Neurology ( IF 5.1 ) Pub Date : 2021-09-06 , DOI: 10.1111/ene.15098
Charidimos Tsagkas _{1,

2,

3} , Yvonne Naegelin ₁ , Michael Amann _{1,

3,

4} , Athina Papadopoulou _{1,

2} , Christian Barro _{1,

5} , M Mallar Chakravarty _{6,

7,

8} , Laura Gaetano ₉ , Jens Wuerfel _{3,

4} , Ludwig Kappos _{1,

2} , Jens Kuhle ₁ , Cristina Granziera _{1,

2,

3,

4} , Till Sprenger _{1,

10} , Stefano Magon ₁₁ , Katrin Parmar _{1,

2}

Affiliation

Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital Basel and University of Basel, Basel, Switzerland.
Translational Imaging in Neurology (ThINK) Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel and University of Basel, Basel, Switzerland.
Medical Image Analysis Center AG, Basel, Switzerland.
Department of Biomedical Engineering, University of Basel, Allschwil, Switzerland.
Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Department of Psychiatry, McGill University, Montreal, QC, Canada.
Cerebral Imaging Centre, Douglas Mental Health University Institute, Verdun, QC, Canada.
Department of Biomedical Engineering, McGill University, Montreal, QC, Canada.
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Department of Neurology, DKD HELIOS Klinik Wiesbaden, Wiesbaden, Germany.
Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

In an era of individualized multiple sclerosis (MS) patient management, biomarkers for accurate prediction of future clinical outcomes are needed. We aimed to evaluate the potential of short-term magnetic resonance imaging (MRI) atrophy measures and serum neurofilament light chain (sNfL) as predictors of the dynamics of disability accumulation in relapse-onset MS.

中文翻译：